The ACR year in review
Articles tagged with "REF News"
Two recent meetings supported by the ACR Research and Education Foundation (REF) provided investigators in disease-targeted research initiatives the opportunity to present on their progress and build collaborations.
Yukiko Kimura, MD, has been interested in medical education for a long time, so when the ACR Research and Education Foundation (REF) awarded her the ACR REF Clinician Scholar Educator Award in 2008, she knew what she wanted to do.
The ACR Research and Education Foundation (REF) has launched the Action Alliance network, a program that calls on rheumatologists, investigators, and health professionals to join the REF in asking patients and families to be a part of the conversation. The Action Alliance consists of two programs working together: From the Field Speakers Bureau and Patients and Families for Progress.
Perhaps the most personally rewarding aspect of working with the ACR Research and Education Foundation (REF) is seeing the success that can come from setting lofty goals. First and foremost, the REF is a goal-oriented organization. The staff and volunteers are not only committed to the goal of ensuring the future of rheumatology, but they aspire to reach high and to lead in this effort.
Although the ACR Research and Education Foundation offers a number of opportunities to students interested in rheumatology, the Ephraim P. Engleman Endowed Resident Research Preceptorship is a unique opportunity that allows for a much more in-depth learning experience. The purpose of the Engleman Preceptorship is to introduce residents to the specialty of rheumatology by supporting a full-time research experience, with the goal of attracting promising physician–scientists to the field of rheumatology early in their careers.
The ACR is pleased to welcome new and returning leaders to the ACR board of directors and ARHP executive committee who were appointed in November. The following members were selected to serve as the newest members-at-large of the ACR board of directors. Each of them shared what they will bring to the table.
A study published in the Journal of Immunology indicates that naturally occurring antibodies in the human immune system have the capacity to suppress inflammatory responses throughout the body. These antibodies may provide researchers an opportunity to develop new therapies for rheumatoid arthritis (RA) and other inflammatory conditions using similar pathways.
A study recently submitted for publication has demonstrated that manipulating T-cell receptor complex–mediated signaling can prevent the development of autoimmune arthritis in mice and may lead to new human therapies without the drawbacks associated with existing treatments.
Research in the laboratory of John D. Mountz, MD, PhD, is opening up a whole new field of study in rheumatoid arthritis (RA).